GIM
SPRO icon

Granahan Investment Management’s Spero Therapeutics SPRO Stock Holding History

Granahan Investment Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-113,322
Closed -$986K – 188
2022
Q1 		$986K Sell
113,322
-265,610
-70% -$2.72M 0.02% 174
2021
Q4 		$6.07M Sell
378,932
-176,682
-32% -$2.81M 0.12% 142
2021
Q3 		$10.2M Buy
555,614
+222,975
+67% +$3.58M 0.19% 112
2021
Q2 		$4.64M Sell
332,639
-9,474
-3% -$132K 0.09% 157
2021
Q1 		$5.04M Sell
342,113
-78,207
-19% -$1.38M 0.11% 141
2020
Q4 		$8.15M Buy
420,320
+46,242
+12% +$721K 0.18% 103
2020
Q3 		$4.17M Buy
374,078
+207,472
+125% +$2.45M 0.14% 117
2020
Q2 		$2.25M Sell
166,606
-4,828
-3% -$54.2K 0.08% 150
2020
Q1 		$1.39M Buy
171,434
+22,567
+15% +$199K 0.07% 154
2019
Q4 		$1.43M Buy
148,867
+1,324
+0.9% +$14.3K 0.07% 149
2019
Q3 		$1.56M Buy
147,543
+9,248
+7% +$97.5K 0.09% 147
2019
Q2 		$1.59M Sell
138,295
-2,231
-2% -$26.9K 0.08% 154
2019
Q1 		$1.8M Sell
140,526
-13,780
-9% -$146K 0.1% 156
2018
Q4 		$949K Sell
154,306
-2,752
-2% -$22.3K 0.07% 166
2018
Q3 		$1.65M Buy
157,058
+5,910
+4% +$68.6K 0.09% 167
2018
Q2 		$2.22M Buy
+151,148
New +$1.93M 0.13% 157

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Granahan Investment Management's SPRO Position: Q2 2022 in Review

Granahan Investment Management sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 113,322 shares — an estimated $986K sold.

Granahan Investment Management first reported a position in SPRO in Q2 2018 and held it in 16 quarters. The position peaked at $10.2M in Q3 2021. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Granahan Investment Management reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Granahan Investment Management sold 113,322 Spero Therapeutics shares in Q2 2022, an estimated $986K.
  • Granahan Investment Management first reported a position in Spero Therapeutics in Q2 2018 and held it in 16 quarters.
  • Granahan Investment Management's Spero Therapeutics position peaked at $10.2M in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Granahan Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.